# First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

> **NCT05271916** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 140 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Dacomitinib+Anlotinib
- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT05271916
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-13
- **Primary completion:** 2025-01-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05271916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05271916, "First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05271916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*